Benson Hill, Inc. (NYSE: BHIL, the “Company” or “Benson Hill”), an ag tech company unlocking the natural genetic diversity of plants, today announced operating and financial results for the quarter ended March 31, 2024....

These results mark another quarter of delivering on expected results driven by a blue chip customer base, durable recurring revenue and high gross margins, which form the basis of its increasing adjusted EBITDA and ongoing leadership in delivering AI-enabled policy and market information. The first quarter of 2024 represented an $8.2 million improvement in adjusted EBITDA year over year and marked the third straight quarter of adjusted EBITDA profitability for FiscalNote....

Today, Abridge announced that the University of Chicago Medicine will make Abridge's gener...

Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical”; the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced the retirement of Andrew Makrides as Chairman of the Board, after serving the Company in this position since 1982. The Board of Directors has appointed Stavros Vizirgianakis Chairman of the Board, effective as of May 7, 2024....

Audax Private Equity (“Audax”), a capital partner for middle and lower middle market companies that seeks to facilitate transformational growth, announced today a recapitalization of portfolio company FDH Aero (“FDH”). This strategic transaction was led by NB Capital Solutions with additional funds advised by Neuberger Berman (together “NB”) joining the ownership group as a significant minority investor. Terms of the deal are not being disclosed....

Benson Hill, Inc. (NYSE: BHIL), an ag tech company unlocking the natural genetic diversity of plants, has named agriculture industry leader Dan Cosgrove as Chief Administrative Officer and General Counsel, effective May 10, 2024. He will assume responsibility for Benson Hill’s day-to-day operations related to business development, compliance, and legal mat...

Kevin Kwilinski, Berry’s CEO said, “Berry once again produced solid financial results, consistent with our expectations. Our teams executed well, offsetting an extended period of sluggish macroeconomic demand along with persistent inflation in our primary raw material to start fiscal 2024. We undertook additional structural enhancements across our businesses and increased our original cost savings target of $140 million to $165 million. We continue to expect a $55 million contribution from the program in fiscal 2024 with the additional $25 million to be realized in fiscal 2025. Moving forward,...

bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird bio” or the “Company”) today reported first quarter results and business highlights for the quarter ended March 31, 2024, including recent commercial and operational progress....

Bruker Corporation (Nasdaq: BRKR) today announced it intends to hold an Investor Webinar from 10 am to about 12 noon Eastern Daylight Time (EDT) on May 17, 2024, to provide additional insights into its three recent acquisitions of Chemspeed, ELITech, and of the NanoString business. Bruker also expects to provide an update to its medium-term financial ou...

Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the first quarter of 2024. For the quarter, revenue was $1.01 billion, a decrease of 1.7% from $1.03 billion in the first quarter of 2023....

Easterly Government Properties, Inc. (NYSE: DEA) (the “Company” or “Easterly”), a fully integrated real estate investment trust (“REIT”) focused primarily on the acquisition, development and management of Class A commercial properties leased to the U.S. Government, announced today that management will participate in investor meetings at Wells Fargo’s 27th Annual Real Estate Securities Conference in Amelia Island, Florida on May 9, 2024....

Energy Recovery, Inc. (Nasdaq: ERII) today announced $15 million in contracts to supply its PX® Pressure Exchanger® energy recovery devices to seawater reverse osmosis (SWRO) desalination plants in India. All orders are expected to ship in 2024....

HanesBrands Inc. (NYSE: HBI), a global leader in iconic apparel brands, today announced results for the first-quarter 2024....

Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today reported its first quarter 2024 results and recent business performance....

Largo Inc. ("Largo" or the "Company") (TSX: LGO) (NASDAQ: LGO) announces a revised release date for its first quarter 2024 financial results to Wednesday, May 15, 2024. The Company will host a conference call to discuss its first quarter 2024 results and other updates on Thursday, May 16 at 10:00 a.m. ET....

LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser solutions for the treatment of cataracts, today announced financial results for the quarter ended March 31, 2024 and provided an update on key operational initiatives....

Orthofix Medical Inc. (NASDAQ:OFIX), a leading global spine and orthopedics company, today announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance to market its Rodeo™ Telescopic Nail....

North American Lithium (“NAL”), the largest producing spodumene operation in North America, achieved record quarterly production of 40,439 dry metric tons (“dmt”) of spodumene concentrate in Q1’24. NAL lithium recoveries of 69% in March 2024 exceeded plan and set a new monthly record. Overall safety performance improved as NAL recorded its lowest quarterly incident rate since the restart of operations in March 2023. Construction of the crushed ore storage dome at NAL was materially completed during Q1’24 with commissioning advancing in Q2’24. This capital project, along with other improvements...

Reflow Medical, Inc., a developer of innovative devices focused on cardiovascular disease, announces completion of enrollment in the DEEPER REVEAL clinical trial (NCT05358353) to evaluate the

Seaport Therapeutics, a clinical-stage biopharmaceutical company that is charting a proven path in neuropsychiatry, today announced two poster presentations detailing the results from multiple clinical trials of SPT-300 at the Society of Biological Psychiatry (SOBP) Annual Meeting in Austin, TX. SPT-300 has been shown to retain the activity and pot...